Matthew Burow

CK2 targeting potentiates antineoplastic effects of dual HER2/EGFR inhibitor lapatinib and attenuates growth factor-induced epithelial-mesenchymal transition

CK2 is a pleiotropic, heterotetrameric kinase elevated in numerous cancers and, as such, has garnered much attention as a target for novel antineoplastic agents. Currently, silmitasertib, a selective CK2 inhibitor, has an orphan designation for medulloblastoma and neuroblastoma....